Evidence map›Paper›PMID 42519118›Full record

ReviewInternational journal of pharmaceutics: X2026

Emerging copper-based hollow nanoplatforms for cancer treatment.

Shuang Liang, Xingran Li, Li Zhang, Wenzhen Zhu, Shaoyan Gan

Abstract readReview
In one paragraph

Review in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuang LiangDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China.
Xingran LiDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China.
Li ZhangState Key Laboratory of New Textile Materials and Advanced Processing, Wuhan Textile University, Wuhan 430200, People's Republic of China.
Wenzhen ZhuDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China.
Shaoyan GanLucky Huaguang Graphics Co., Ltd, Nanyang 473000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomedicines have significantly advanced tumor treatment, with hollow copper (Cu)-based nanostructures emerging as a uniquely promising nanoplatform. Their degradable frameworks enable controlled release of various therapeutic agents, facilitating chemotherapy, photothermal therapy (PTT), photodynamic therapy (PDT), immunotherapy, and related modalities. Simultaneously, liberated Cu ions drive chemodynamic therapy (CDT) via Fenton-like reactions and trigger cuproptosis. A critical effect of this combined action is the induction of immunogenic cell death (ICD), thereby amplifying antitumor immunity. Moreover, the inherent physicochemical properties of these nanostructures support multimodal diagnostic functions, which enable accurate imaging-guided interventions. Herein, we present a systematic overview of the latest developments in hollow Cu-based nanoplatforms, covering inorganic Cu nanostructures, Cu-doped composites, matrix-supported Cu systems, and Cu-based complexes, for diverse cancer therapies. We also discuss rational design strategies to achieve synergistic therapeutic outcomes and conclude with an analysis of translational challenges and future directions toward clinical adoption.

Indexed as

Chemodynamic therapyCopperCuproptosisHollow nanoplatformsSynergistic therapeutic outcomes

Identifiers

PMID42519118
PMCPMC13382424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.